drugset / Trial / NCT00176930
Stem Cell Transplant for Hematological Malignancy
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
Timeline
- Start
- 2001-10
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Busulfan | Small molecule | 0.8 mg/kg | Intravenous |
| Background | CD4+/CD25+ cells | Unknown | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 60 mg/kg | Intravenous |
| Background | Equine ATG | Unknown | 15 mg/kg | Intravenous |